Have a feature idea you'd love to see implemented?
Let us know!
TOVX Theriva Biologics Inc
Price (delayed)
$1.28
Market cap
$3.56M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$33.31
Enterprise value
-$11.21M
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company's
Highlights
The debt has declined by 22% year-on-year and by 5% since the previous quarter
TOVX's equity is down by 40% YoY and by 4.9% from the previous quarter
The net income has decreased by 38% YoY and by 20% QoQ
Key stats
What are the main financial stats of TOVX
Market
Valuations
Earnings
Shares outstanding
2.78M
Market cap
$3.56M
Enterprise value
-$11.21M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$27.12M
EBITDA
-$26.53M
Free cash flow
-$18.84M
Per share
Balance sheet
Liquidity
EPS
-$33.31
Free cash flow per share
-$16.61
Book value per share
$24.51
Revenue per share
$0
TBVPS
$35.36
Total assets
$40.11M
Total liabilities
$15.47M
Debt
$1.74M
Equity
$24.64M
Working capital
$12.21M
Debt to equity
0.07
Current ratio
2.67
Quick ratio
2.25
Net debt/EBITDA
0.56
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.3%
Return on equity
-89.8%
Return on invested capital
-136.1%
Return on capital employed
-82.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TOVX stock price
How has the Theriva Biologics stock price performed over time
Intraday
1.59%
1 week
-5.19%
1 month
-13.51%
1 year
-88.85%
YTD
-88.09%
QTD
-7.25%
Financial performance
How have Theriva Biologics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$27.98M
Net income
-$26.69M
Gross margin
N/A
Net margin
N/A
The net income has decreased by 38% YoY and by 20% QoQ
The company's operating income fell by 24% YoY and by 15% QoQ
Growth
What is Theriva Biologics's growth rate over time
Valuation
What is Theriva Biologics stock price valuation
P/E
N/A
P/B
0.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Theriva Biologics's EPS has decreased by 6% from the previous quarter and by 4.6% YoY
TOVX's P/B is 93% below its 5-year quarterly average of 0.7 and 75% below its last 4 quarters average of 0.2
TOVX's equity is down by 40% YoY and by 4.9% from the previous quarter
Efficiency
How efficient is Theriva Biologics business performance
The ROE has shrunk by 116% YoY and by 36% QoQ
The ROA has plunged by 98% YoY and by 34% from the previous quarter
The return on invested capital has declined by 23% year-on-year and by 17% since the previous quarter
Dividends
What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TOVX.
Financial health
How did Theriva Biologics financials performed over time
The total assets is 159% more than the total liabilities
The quick ratio has decreased by 37% YoY and by 8% from the previous quarter
The total assets has contracted by 35% YoY and by 5% from the previous quarter
The debt is 93% smaller than the equity
The debt to equity has grown by 40% YoY
TOVX's equity is down by 40% YoY and by 4.9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.